LFSC F/M Emerald Life Sciences Innovation ETF
The F/M Emerald Life Sciences Innovation ETF (LFSC) strategically invests in pioneering life science enterprises. Its core objective is to identify companies that are well-positioned for substantial long-term growth and the creation of significant value. As an actively managed fund, LFSC benefits from a highly specialized and experienced team dedicated to conducting in-depth research into complex life sciences firms. The fund primarily targets U.S. equity securities, selecting those that demonstrate strong growth potential. Specific criteria for inclusion involve a company's leadership in technological advancement, its capacity for market disruption, or its innovative application of artificial intelligence. The expansive field of life sciences, as defined by the fund, encompasses various sectors including biotechnology, pharmaceuticals, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection is guided by a rigorous and extensive 10-step research framework. This meticulous process incorporates: Reviews of publicly accessible and external third-party information. Comprehensive peer reviews. Development of detailed financial and valuation models. In-house research and surveys. Direct engagement and interviews with company management, industry and medical experts, and supply chain representatives. Robust internal collaboration among the investment team. While its primary focus is on domestic equities, the fund retains the flex
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| LFSC | +11.0% | -2.9% | +24.1% | +36.3% | +22.0% | +12.7% |
| Equity average (4611 funds) | -2.1% | +2.7% | +87.9% | +61379.8% | +13.9% | +2.3% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: +$3K net.
Holdings · as of Nov 13, 2026
| # | Holding | Weight |
|---|---|---|
| 1 | REPL Replimune Group Inc | 10.49% |
| 2 | LIVN LivaNova PLC | 7.44% |
| 3 | TVTX Travere Therapeutics Inc | 5.67% |
| 4 | COGT Cogent Biosciences Inc | 5.38% |
| 5 | BLLN Billiontoone Inc | 4.63% |
| 6 | GH Guardant Health Inc | 4.53% |
| 7 | MANE VeraDermics Inc | 4.50% |
| 8 | SYRE Spyre Therapeutics Inc | 4.28% |
| 9 | CORT Corcept Therapeutics Inc | 3.99% |
| 10 | UTHR United Therapeutics Corp | 3.72% |
| 11 | MIRM Mirum Pharmaceuticals Inc | 3.64% |
| 12 | TMDX TransMedics Group Inc | 3.58% |
| 13 | CYTK Cytokinetics Inc | 2.85% |
| 14 | ICUI ICU Medical Inc | 2.82% |
| 15 | AXSM Axsome Therapeutics Inc | 2.66% |
| 16 | SVRA Savara Inc | 2.63% |
| 17 | PVLA Palvella Therapeutics Inc | 2.29% |
| 18 | TRVI Trevi Therapeutics Inc | 2.28% |
| 19 | PRAX Praxis Precision Medicines Inc | 2.23% |
| 20 | CBLL Ceribell Inc | 1.99% |
| 21 | VRDN Viridian Therapeutics Inc | 1.87% |
| 22 | TWST Twist Bioscience Corp | 1.77% |
| 23 | NKTR Nektar Therapeutics | 1.58% |
| 24 | DNTH Dianthus Therapeutics Inc | 1.57% |
| 25 | CRVS Corvus Pharmaceuticals Inc | 1.53% |
| 26 | VCEL Vericel Corp | 1.46% |
| 27 | ALMR Alamar Biosciences Inc | 1.13% |
| 28 | NEO NeoGenomics Inc | 1.13% |
| 29 | GMED Globus Medical Inc | 0.99% |
| 30 | RDNT RadNet Inc | 0.94% |
| 31 | ATEC Alphatec Holdings Inc | 0.86% |
| 32 | WAY Waystar Holding Corp | 0.74% |
| 33 | KRRO Korro Bio Inc | 0.73% |
| 34 | SENS Senseonics Holdings Inc | 0.61% |
| 35 | HNGE Hinge Health Inc | 0.61% |
| 36 | WVE Wave Life Sciences Inc | 0.42% |
| 37 | RBIL F/m Ultrashort Treasury Inflation-Protected Security TIPS ETF | 0.35% |
| 38 | OBIL F/m US Treasury 12 Month Bill ETF | 0.10% |
| 39 | LFSC Cash & Other | 0.00% |
Sector breakdown
Country breakdown
Distributions
No distributions on file.
Members of Congress who disclosed this ETF
No member of Congress has disclosed a trade in LFSC in the filings we hold.
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error
